Cargando…

The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis

Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yan, He, Meizhi, Zhou, Yaoyao, Yang, Chen, Wei, Shuyi, Bian, Xiaohui, Christopher, Odong, Xie, Lang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403169/ https://www.ncbi.nlm.nih.gov/pubmed/30873025 http://dx.doi.org/10.3389/fphar.2019.00139

Ejemplares similares

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis
por: Zhu, Lei, et al.
Publicado: (2019)

Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis
por: Yang, Lianzhou, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis
por: Shen, Zefeng, et al.
Publicado: (2019)

Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis
por: Wang, Shuxia, et al.
Publicado: (2020)

Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis
por: Xie, Qinfen, et al.
Publicado: (2020)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
por: Chen, Ruo Qiao, et al.
Publicado: (2019)

The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis
por: Xu, Gang, et al.
Publicado: (2019)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis
por: Zheng, Chuanxi, et al.
Publicado: (2018)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
por: Deng, Siyao, et al.
Publicado: (2019)

The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
por: Zeng, Siyuan, et al.
Publicado: (2023)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
por: Ding, Xiangli, et al.
Publicado: (2019)

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis
por: Lu, Ling, et al.
Publicado: (2020)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

Clinicopathological analysis of PD-L2 expression in colorectal cancer
por: Guo, Peng-Da, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials
por: Gu, Lihu, et al.
Publicado: (2022)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

The relationship between pancreatic cancer and type 2 diabetes: cause and consequence
por: Li, Yan, et al.
Publicado: (2019)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma
por: Li, Yan, et al.
Publicado: (2018)

Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1
por: Pan, Xiaohui, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
por: Zhao, Mingye, et al.
Publicado: (2022)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients
por: Lu, Yi, et al.
Publicado: (2020)

Chinese herbal medicine for threatened miscarriage: An updated systematic review and meta-analysis
por: Xie, Hongliang, et al.
Publicado: (2023)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis
por: Zeng, Qiang, et al.
Publicado: (2020)

Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis
por: Qi, Yingjie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ftdrdlmtb8ni9sg06drga9o262